Akeso's Ivonescimab Receives NMPA Approval for First-Line Squamous Non-Small Cell Lung Cancer in China

Akeso has secured approval from China's National Medical Products Administration (NMPA) for ivonescimab, in combination with chemotherapy, for the treatment of first-line squamous non-small cell lung cancer (sq-NSCLC). This regulatory action marks the third major approval for ivonescimab.